基本信息
浏览量:3
职业迁徙
个人简介
Dr. Arterburn’s research program focuses on the development of small molecular probes, imaging agents, anticancer and antiviral drugs. We employ innovative strategies using modern methods of organic and organometallic synthetic chemistry for the synthesis of conjugates, broadly impacting the multidisciplinary fields of drug development and chemical biology, and addressing fundamental problems in chemistry, biology and medicine. One representative major success story stems from a long-standing commitment to cancer research. In this field, his work involving the synthesis of estrogen imaging agents, and a productive research collaboration with Dr.’s Prossnitz, Oprea, Hathaway and Sklar from the UNM Cancer Center, has recently revealed an entirely new type of estrogen receptor named GPR30 (also called GPER). This receptor is found in breast, ovarian and endometrial tissues, as well as in aggressive cancer cell lines that lack other estrogen receptors. It is also associated with lower survival rates in endometrial cancer patients, and higher risk of developing metastatic disease in breast cancer. The importance of the nuclear estrogen receptors ER?/? to breast cancer is widely recognized among cancer researchers. GPR30 mediates some of the same cellular responses as the conventional estrogen receptor but utilizes distinct biochemical signaling pathways. Anti-estrogen drugs such as Tamoxifen and Faslodex, were developed to target the classical forms of estrogen receptors. However, such anti-estrogens can produce unexpected and potentially harmful interactions in cells that harbor GPR30. Because of the importance of estrogen-mediated signaling in breast, ovarian and endometrial cancers, GPR30 is believed to play an important role in the development and/or progression of these cancers. GPR30 may represent both a novel biomarker for diagnostic/prognostic/treatment stratification. It may also provide a therapeutic focus for the targeted treatment of these cancers. We have developed new diagnostics, imaging agents, and therapeutics based on the synthetic tetrahydro-3H-cyclopenta[c]quinoline scaffold that selectively target GPR30. We are designing new agents capable of detecting GPR30 as a biomarker by non-invasive imaging for early diagnosis, and to control its activity in order to alter the course of cancer formation and progression. The teams’ initial 2005 publication in Science described GPR30-estrogen binding and non-genomic signaling pathways, a subsequent 2006 paper in Nature Chemical Biology reported the discovery of the first GPR30 selective agonist G-1, the synthesis and in vivo characterization of the first GPR30 antagonist G15 was published in Nature Chemical Biology in 2009, and a second generation GPR30 antagonist G36 was recently published in J. Steroid Biochem & Mol Biol. These probes are currently being used in laboratories around the world to distinguish GPR30-mediated physiological effects and have already attracted tremendous scientific interest. U.S. patent S.N. 11/497,751 was awarded for this invention, and N12-071USDIV divisional application was filed recently to include isotopically labeled analogs for biomedical applications.
研究兴趣
论文共 150 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Chetana M Revankar,Cristian G Bologa,Richard A Pepermans,Geetanjali Sharma,Whitney K Petrie, Sara N Alcon,Angela S Field,Chinnasamy Ramesh,Matthew A Parker, Nikolay P Savchuk,Larry A Sklar,Helen J Hathaway,
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn